Major Adverse Cardiovascular Events After Colchicine Administration Before Percutaneous Coronary Intervention: Follow-Up of the Colchicine-PCI Trial.

Periprocedural inflammation is associated with major adverse cardiovascular events in patients who undergo percutaneous coronary intervention (PCI). In the contemporary era, 5% to 10% of patients develop restenosis, and in the acute coronary syndrome cohort, there remains a 20% major adverse cardiovascular events rate at 3 years, half of which are culprit-lesion related. In patients at risk of restenosis, colchicine has been shown to reduce restenosis when started within 24 hours of PCI and continued for 6 months thereafter, compared with placebo. The Colchicine-PCI trial, which randomized patients to a 1-time loading dose of colchicine or placebo 1 to 2 hours before PCI, showed a dampening of the inflammatory response to PCI but no difference in postprocedural myocardial injury. On mean follow-up of 3.3 years, the incidence of major adverse cardiovascular events did not differ between colchicine and placebo groups (32.5% vs 34.9%; hazard ratio 0.95 [0.68 to 1.34]).

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Dr. Shah receives grant funding from the Veterans Affairs Office of Research and Development and National Institutes of Health/National Heart Lung Blood Institute; serves on the advisory board for Philips Volcano and Horizon Therapeutics; and serves as a consultant for Terumo Medical. Dr. Smilowitz serves on the advisory board for Abbott. Dr. Feit is a shareholder of Boston Scientific, Medtronic, and Johnson and Johnson. Dr. Katz has research grant funding from Pfizer, Luitpold, AMAG Pharmaceuticals, Biocardia, and Array BioPharma and serves on a data safety monitoring board for Salubris Bio. Dr. Cronstein is a consultant to marvel Biosciences, has research grant funding from Regensoine, and is a founder of Regenosine, Inc. Dr. Pillinger serves as a consultant for Horizon, Sobi, and Fortress Biotech, and is the recipient of investigator-initiated grant support from Hikma and Horizon. The remaining authors have no competing interests to declare.